Literature DB >> 15841106

Quantitative PET studies of the serotonin transporter in MDMA users and controls using [11C]McN5652 and [11C]DASB.

Una D McCann1, Zsolt Szabo, Esen Seckin, Peter Rosenblatt, William B Mathews, Hayden T Ravert, Robert F Dannals, George A Ricaurte.   

Abstract

(+/-)3,4-Methylenedioxymethamphetamine (MDMA, 'Ecstasy') is a widely used illicit drug that produces toxic effects on brain serotonin axons and axon terminals in animals. The results of clinical studies addressing MDMA's serotonin neurotoxic potential in humans have been inconclusive. In the present study, 23 abstinent MDMA users and 19 non-MDMA controls underwent quantitative positron emission tomography (PET) studies using [11C]McN5652 and [11C]DASB, first- and second-generation serotonin transporter (SERT) ligands previously validated in baboons for detecting MDMA-induced brain serotonin neurotoxicity. Global and regional distribution volumes (DVs) and two additional SERT-binding parameters (DV(spec) and DVR) were compared in the two subject populations using parametric statistical analyses. Data from PET studies revealed excellent correlations between the various binding parameters of [11C]McN5652 and [11C]DASB, both in individual brain regions and individual subjects. Global SERT reductions were found in MDMA users with both PET ligands, using all three of the above-mentioned SERT-binding parameters. Preplanned comparisons in 15 regions of interest demonstrated reductions in selected cortical and subcortical structures. Exploratory correlational analyses suggested that SERT measures recover with time, and that loss of the SERT is directly associated with MDMA use intensity. These quantitative PET data, obtained using validated first- and second-generation SERT PET ligands, provide strong evidence of reduced SERT density in some recreational MDMA users.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15841106      PMCID: PMC2034411          DOI: 10.1038/sj.npp.1300736

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  35 in total

1.  Column-switching HPLC for the analysis of plasma in PET imaging studies.

Authors:  J Hilton; F Yokoi; R F Dannals; H T Ravert; Z Szabo; D F Wong
Journal:  Nucl Med Biol       Date:  2000-08       Impact factor: 2.408

2.  Effects of MDMA (ecstasy) use and abstention on serotonin neurons.

Authors:  P M Haddad; P Strickland; I Anderson; J F W Deakin; S M Dursun
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

3.  Imaging the serotonin transporter with positron emission tomography: initial human studies with [11C]DAPP and [11C]DASB.

Authors:  S Houle; N Ginovart; D Hussey; J H Meyer; A A Wilson
Journal:  Eur J Nucl Med       Date:  2000-11

4.  Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurons.

Authors:  L Reneman; J Booij; K de Bruin; J B Reitsma; F A de Wolff; W B Gunning; G J den Heeten; W van den Brink
Journal:  Lancet       Date:  2001-12-01       Impact factor: 79.321

5.  Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study.

Authors:  J H Meyer; A A Wilson; N Ginovart; V Goulding; D Hussey; K Hood; S Houle
Journal:  Am J Psychiatry       Date:  2001-11       Impact factor: 18.112

6.  Long-term impairment of anterograde axonal transport along fiber projections originating in the rostral raphe nuclei after treatment with fenfluramine or methylenedioxymethamphetamine.

Authors:  B T Callahan; B J Cord; G A Ricaurte
Journal:  Synapse       Date:  2001-05       Impact factor: 2.562

7.  Comparison of (+)-(11)C-McN5652 and (11)C-DASB as serotonin transporter radioligands under various experimental conditions.

Authors:  Zsolt Szabo; Una D McCann; Alan A Wilson; Ursula Scheffel; Taofeek Owonikoko; William B Mathews; Hayden T Ravert; John Hilton; Robert F Dannals; George A Ricaurte
Journal:  J Nucl Med       Date:  2002-05       Impact factor: 10.057

8.  Cortical serotonin transporter density and verbal memory in individuals who stopped using 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy"): preliminary findings.

Authors:  L Reneman; J Lavalaye; B Schmand; F A de Wolff; W van den Brink; G J den Heeten; J Booij
Journal:  Arch Gen Psychiatry       Date:  2001-10

9.  Kinetic analysis of [11C]McN5652: a serotonin transporter radioligand.

Authors:  Z Szabo; U Scheffel; W B Mathews; H T Ravert; K Szabo; M Kraut; S Palmon; G A Ricaurte; R F Dannals
Journal:  J Cereb Blood Flow Metab       Date:  1999-09       Impact factor: 6.200

Review 10.  (+/-)3,4-Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: clinical studies.

Authors:  U D McCann; V Eligulashvili; G A Ricaurte
Journal:  Neuropsychobiology       Date:  2000       Impact factor: 2.328

View more
  69 in total

1.  Evidence for chronically altered serotonin function in the cerebral cortex of female 3,4-methylenedioxymethamphetamine polydrug users.

Authors:  Christina R Di Iorio; Tristan J Watkins; Mary S Dietrich; Aize Cao; Jennifer U Blackford; Baxter Rogers; Mohammed S Ansari; Ronald M Baldwin; Rui Li; Robert M Kessler; Ronald M Salomon; Margaret Benningfield; Ronald L Cowan
Journal:  Arch Gen Psychiatry       Date:  2011-12-05

2.  Ecstasy (MDMA) Alters Cardiac Gene Expression and DNA Methylation: Implications for Circadian Rhythm Dysfunction in the Heart.

Authors:  Christopher A Koczor; Ivan Ludlow; Robert S Hight; Zhe Jiao; Earl Fields; Tomika Ludaway; Rodney Russ; Rebecca A Torres; William Lewis
Journal:  Toxicol Sci       Date:  2015-08-06       Impact factor: 4.849

3.  The effect of polymorphism at the serotonin transporter gene on decision-making, memory and executive function in ecstasy users and controls.

Authors:  Jonathan P Roiser; Robert D Rogers; Lynnette J Cook; Barbara J Sahakian
Journal:  Psychopharmacology (Berl)       Date:  2006-08-29       Impact factor: 4.530

4.  MDMA (Ecstasy) use and psychiatric problems.

Authors:  Casey R Guillot; Mitchell E Berman
Journal:  Psychopharmacology (Berl)       Date:  2006-10-24       Impact factor: 4.530

5.  Occipital cortical proton MRS at 4 Tesla in human moderate MDMA polydrug users.

Authors:  Ronald L Cowan; Nicolas R Bolo; Mary Dietrich; Erica Haga; Scott E Lukas; Perry F Renshaw
Journal:  Psychiatry Res       Date:  2007-06-18       Impact factor: 3.222

6.  Anxiety, depression, and behavioral symptoms of executive dysfunction in ecstasy users: contributions of polydrug use.

Authors:  Krista Lisdahl Medina; Paula K Shear
Journal:  Drug Alcohol Depend       Date:  2006-10-30       Impact factor: 4.492

7.  Mechanisms of dopaminergic and serotonergic neurotransmission in Tourette syndrome: clues from an in vivo neurochemistry study with PET.

Authors:  Dean F Wong; James R Brasić; Harvey S Singer; David J Schretlen; Hiroto Kuwabara; Yun Zhou; Ayon Nandi; Marika A Maris; Mohab Alexander; Weiguo Ye; Olivier Rousset; Anil Kumar; Zsolt Szabo; Albert Gjedde; Anthony A Grace
Journal:  Neuropsychopharmacology       Date:  2007-11-07       Impact factor: 7.853

8.  Neuroimaging in human MDMA (Ecstasy) users.

Authors:  Ronald L Cowan; Deanne M Roberts; James M Joers
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

9.  Sleep apnea in young abstinent recreational MDMA ("ecstasy") consumers.

Authors:  Una D McCann; Francis P Sgambati; Alan R Schwartz; George A Ricaurte
Journal:  Neurology       Date:  2009-12-02       Impact factor: 9.910

10.  First D1-like receptor PET imaging of the rat and primate kidney: implications for human disease monitoring.

Authors:  Michael L Granda; Frederick A Schroeder; Ronald H J Borra; Nathan Schauer; Ehimen Aisaborhale; Alexander R Guimaraes; Jacob M Hooker
Journal:  Am J Physiol Renal Physiol       Date:  2014-05-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.